secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001641172-25-023715
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona reports Q2 net income of $108.8M on PRV sale; ZEVASKYN launch on track
-----------------------------------------------------------------------------

- Net income $108.8M ($2.07 basic EPS) vs $7.4M in Q2 2024; includes $155M gain from PRV sale.
- Cash $225.9M expected to fund operations over two years without anticipated ZEVASKYN revenue.
- First ZEVASKYN patient treatment expected in Q3 2025; multiple patients identified at QTCs.
- 100% of prior authorization requests approved; United Healthcare issued favorable coverage policy.
- R&D expense fell to $5.9M; SG&A rose to $17.1M due to commercial launch costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000164117225023715/0001641172-25-023715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000164117225023715/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer